Breaking News


Reduction of depression symptoms in patients with moderate-severe psoriasis: A controlled study with adalimumab


A 12-week randomized, placebo-controlled, double-blind study assessed the effects of adalimumab (40 mg on alternate weeks) versus placebo on depression self-rating scores in 96 patients with moderate-severe psoriasis. The primary efficacy measure was the change in Zung Self-Rating Depression Scale (ZDS) scores from baseline to week 12. The adalimumab group (n = 44) experienced an additional  6-point fall in ZDS scores compared with the placebo group at week 12 (P < 0.001). Improvement in depressive symptoms correlated with improvement in the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) (both r = 0.5; P < 0.0001). There was a greater ZDS score improvement in responders with a ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list